Copyright © 2019 Qrono Inc.  

 All Rights Reserved.

Technology to Change the Tumor-Immune Dialogue

Cancer masks its identity and threat with immunosuppressive signals

Invasive cancer maintains a steady discourse with regulatory cells that blocks the adaptive immune system and promotes disease progression.  Standard chemo- or immunotherapies, which act on patients over hours or days, do little to change cancer’s month-by-month buildup of pro-metastasis, pro-growth signaling.  Qrono’s Eloquent™ platform uses mathematically optimized polymer particles to start healthy dialogues along conserved pathways by delivering the right amount of agent at the right rate to the right cells.  Each of these patentable drug-polymer-particle combinations offers a unique way to unmask the threat posed by a patient's cancer and make it the focus of a robust adaptive immune response.


Eloquent™ therapy creates a tumor-immune dialogue that voices cancer’s threat

Prolonged cell stress activates pathways within cancer that can supersede its anti-immune, pro-growth signaling.  Stressed cancer cells produce “danger” signals and uniquely mutated proteins called neoantigens that together tell antigen presenting cells (APCs) the best way to direct a patient’s adaptive immune system.   This process, however, is a sensitive one and many agents that could initiate it simply kill cancer cells too rapidly for immunogenic signaling to occur.  Eloquent™ therapy class QR20x gradually and consistently escalates cancer cell stress levels over a period of weeks to achieve greater neoantigen and danger signal production than equivalent or higher doses of immunogenic drug or antibody therapies.


Eloquent™ therapy helps antigen presenting cells convey cancer's threat to T cells

Feedback-loops within antigen presenting cells (APCs) inherently limit the strength of immunotherapy-initiated T cell responses that could otherwise cure cancer.  Inhibiting feedback within neoantigen-rich APCs builds stronger cancer-specific T cell responses than therapy from targeted immunogenic agents. Yet specificity is critical, as misdirected inhibition could easily damage healthy tissues.  Eloquent™ therapy only inhibits feedback in the APCs that phagocytize neoantigens.  We expect class QR21x therapies to drive the expansion of T cells that infiltrate metastatic cancer and protect against recurrence more effectively than genetically engineering cell therapies.